Carlo Alberto Scirè1, Greta Carrara2, Anna Zanetti3, Gianpiero Landolfi2, Cecilia Chighizola4, Alessia Alunno5, Laura Andreoli6, Roberto Caporali7, Roberto Gerli5, Gian Domenico Sebastiani8, Guido Valesini9, Luigi Sinigaglia10. 1. Epidemiology Research Unit, Italian Society for Rheumatology, Milan, and Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy. 2. Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy. 3. Epidemiology Research Unit, Italian Society for Rheumatology, Milan, and Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy. 4. Experimental Laboratory of Immunological and Rheumatologic Researches, Immunology and Rheumatology Unit, San Luca Hospital, IRCCS Istituto Auxologico Italiano, Milan, Italy. 5. Rheumatology Unit, Department of Medicine, University of Perugia, Italy. 6. Rheumatology and Clinical Immunology Unit, ASST Spedali Civili; Department of Clinical and Experimental Sciences, University of Brescia, Italy. 7. Department of Clinical Sciences and Community Health, University of Milan, ASST Pini CTO, Milan, Italy. 8. Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy. 9. Rheumatology, Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Italy. 10. Italian Society for Rheumatology, Milan, Italy.
Abstract
OBJECTIVES: Italy was one of the first countries significantly affected by the coronavirus disease 2019 (COVID-19) epidemic. The Italian Society for Rheumatology promptly launched a retrospective and anonymised data collection to monitor COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs), the CONTROL-19 surveillance database, which is part of the COVID-19 Global Rheumatology Alliance. METHODS: CONTROL-19 includes patients with RMDs and proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) updated until May 3rd 2020. In this analysis, only molecular diagnoses were included. The data collection covered demographic data, medical history (general and RMD-related), treatments and COVID-19 related features, treatments, and outcome. In this paper, we report the first descriptive data from the CONTROL-19 registry. RESULTS: The population of the first 232 patients (36% males) consisted mainly of elderly patients (mean age 62.2 years), who used corticosteroids (51.7%), and suffered from multi-morbidity (median comorbidities 2). Rheumatoid arthritis was the most frequent disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). Most cases had an active disease (69.4%). Clinical presentation of COVID-19 was typical, with systemic symptoms (fever and asthenia) and respiratory symptoms. The overall outcome was severe, with high frequencies of hospitalisation (69.8%), respiratory support oxygen (55.7%), non-invasive ventilation (20.9%) or mechanical ventilation (7.5%), and 19% of deaths. Male patients typically manifested a worse prognosis. Immunomodulatory treatments were not significantly associated with an increased risk of intensive care unit admission/mechanical ventilation/death. CONCLUSIONS: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMD patients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments.
OBJECTIVES: Italy was one of the first countries significantly affected by the coronavirus disease 2019 (COVID-19) epidemic. The Italian Society for Rheumatology promptly launched a retrospective and anonymised data collection to monitor COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs), the CONTROL-19 surveillance database, which is part of the COVID-19 Global Rheumatology Alliance. METHODS: CONTROL-19 includes patients with RMDs and proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) updated until May 3rd 2020. In this analysis, only molecular diagnoses were included. The data collection covered demographic data, medical history (general and RMD-related), treatments and COVID-19 related features, treatments, and outcome. In this paper, we report the first descriptive data from the CONTROL-19 registry. RESULTS: The population of the first 232 patients (36% males) consisted mainly of elderly patients (mean age 62.2 years), who used corticosteroids (51.7%), and suffered from multi-morbidity (median comorbidities 2). Rheumatoid arthritis was the most frequent disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). Most cases had an active disease (69.4%). Clinical presentation of COVID-19 was typical, with systemic symptoms (fever and asthenia) and respiratory symptoms. The overall outcome was severe, with high frequencies of hospitalisation (69.8%), respiratory support oxygen (55.7%), non-invasive ventilation (20.9%) or mechanical ventilation (7.5%), and 19% of deaths. Male patients typically manifested a worse prognosis. Immunomodulatory treatments were not significantly associated with an increased risk of intensive care unit admission/mechanical ventilation/death. CONCLUSIONS: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMDpatients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments.
Authors: Richard Conway; Elena Nikiphorou; Christiana A Demetriou; Candice Low; Kelly Leamy; John G Ryan; Ronan Kavanagh; Alexander D Fraser; John J Carey; Paul O'Connell; Rachael M Flood; Ronan H Mullan; David J Kane; Philip C Robinson; Jean W Liew; Rebecca Grainger; Geraldine M McCarthy Journal: Rheumatol Adv Pract Date: 2021-05-13
Authors: Zara Izadi; Milena A Gianfrancesco; Alfredo Aguirre; Anja Strangfeld; Elsa F Mateus; Kimme L Hyrich; Laure Gossec; Loreto Carmona; Saskia Lawson-Tovey; Lianne Kearsley-Fleet; Martin Schaefer; Andrea M Seet; Gabriela Schmajuk; Lindsay Jacobsohn; Patricia Katz; Stephanie Rush; Samar Al-Emadi; Jeffrey A Sparks; Tiffany Y-T Hsu; Naomi J Patel; Leanna Wise; Emily Gilbert; Alí Duarte-García; Maria O Valenzuela-Almada; Manuel F Ugarte-Gil; Sandra Lúcia Euzébio Ribeiro; Adriana de Oliveira Marinho; Lilian David de Azevedo Valadares; Daniela Di Giuseppe; Rebecca Hasseli; Jutta G Richter; Alexander Pfeil; Tim Schmeiser; Carolina A Isnardi; Alvaro A Reyes Torres; Gelsomina Alle; Verónica Saurit; Anna Zanetti; Greta Carrara; Julien Labreuche; Thomas Barnetche; Muriel Herasse; Samira Plassart; Maria José Santos; Ana Maria Rodrigues; Philip C Robinson; Pedro M Machado; Emily Sirotich; Jean W Liew; Jonathan S Hausmann; Paul Sufka; Rebecca Grainger; Suleman Bhana; Wendy Costello; Zachary S Wallace; Jinoos Yazdany Journal: ACR Open Rheumatol Date: 2022-07-22
Authors: Ana Rita Cruz-Machado; Sofia C Barreira; Matilde Bandeira; Marc Veldhoen; Andreia Gomes; Marta Serrano; Catarina Duarte; Maria Rato; Bruno Miguel Fernandes; Salomé Garcia; Filipe Pinheiro; Miguel Bernardes; Nathalie Madeira; Cláudia Miguel; Rita Torres; Ana Bento Silva; Jorge Pestana; Diogo Almeida; Carolina Mazeda; Filipe Cunha Santos; Patrícia Pinto; Marlene Sousa; Hugo Parente; Graça Sequeira; Maria José Santos; João Eurico Fonseca; Vasco C Romão Journal: Front Med (Lausanne) Date: 2022-06-13
Authors: David M G Halpin; Adrian Paul Rabe; Wei Jie Loke; Stacy Grieve; Patrick Daniele; Sanghee Hwang; Anna Forsythe Journal: J Asthma Allergy Date: 2022-06-17
Authors: Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Zhanguo Li; Jose Paulo Lorenzo; Worawit Louthrenoo; Catherine Hill; Kevin Pile; Philip C Robinson; Leonila F Dans; Li Yang Hsu; Sang-Min Lee; Jiacai Cho; A T M Tanveer Hasan; Babur Salim; Saba Samreen; Syahrul Sazliyana Shaharir; Priscilla Wong; Jeffrey Chau; Debashish Danda; Syed Atiqul Haq Journal: Int J Rheum Dis Date: 2021-05-04 Impact factor: 2.454
Authors: Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi Journal: J Autoimmun Date: 2020-12-14 Impact factor: 7.094
Authors: D Sofia Villacis-Nunez; Christina A Rostad; Kelly Rouster-Stevens; Arezou Khosroshahi; Shanmuganathan Chandrakasan; Sampath Prahalad Journal: Pediatr Rheumatol Online J Date: 2021-06-21 Impact factor: 3.054